Name:
Dr Richard Hargreaves PhD HonFBPhS
Organisation:
Bristol Myers Squibb
Year elected:
2015
Primary professional setting:
Industry
Richard Hargreaves holds a BSc and Ph.D. from Chelsea/Kings College, London University UK He is currently Senior VP Head of Neuroscience Research and Early Development at Bristol Myers Squibb. Previously Corporate VP, Head of Neuroscience and Imaging Research at Celgene, VP, Head of the New Indications Research Unit (NIRU) and Research & Early Development Centers of Excellence (RED-CoEs) at Biogen and VP Discovery Head for Neuroscience and VP Imaging in Merck Research Laboratories. Richard has led teams that have advanced numerous novel CNS PET imaging agents and neuroscience drug candidates to the clinic contributing to the successful registration of MAXALT® for migraine, EMEND® and EMEND-IV® for chemotherapy-induced nausea and vomiting, BELSOMRA ® for insomnia, Ajovy® for prevention of migraine, Ubrelvy® for acute migraine and Zeposia® for relapsing multiple sclerosis. He is a board member for Target ALS and on the SAB for the Silverstein Parkinson’s disease foundation. Richard has published >200 journal articles and been recognized by awards from the ASPCT for his work on CNS discovery imaging and the BPS with the Sir James Black Award for Drug Discovery.